h)(13) YOUR COPY RUSSELL EQUITY INDEXES RESEARCH LICENSE AGREEMENT This License Agreement (hereinafter the "Agreement") is entered into this 3rd day of MARCH 1999 (hereinafter the "Effective Date"), by and between FRANK RUSSELL COMPANY (hereinafter...Research License Agreement • October 1st, 1999 • Value Equity Trust • Washington
CONFIDENTIALResearch License Agreement • February 26th, 2016 • Oncobiologics, Inc. • Biological products, (no disgnostic substances)
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
AGREEMENT Between NEW YORK UNIVERSITY and COLLATERAL THERAPEUTICS, INC.Research & License Agreement • December 22nd, 2005 • Aries Ventures Inc • Biological products, (no disgnostic substances)
ATTENTION: With acquisition of the PARGE software you agree to the following license contract.Research License Agreement • November 6th, 2001
Whereas the ‘Licensor’ is the company ‘ReSe Applications Schläpfer’ of Wil (Switzerland) and the Licensee is the company, institute, or individual acquiring the software. The terms ‘Software’ and ‘PARGE’ are used for the com- plete software installation as distributed through the web.
RESEARCH LICENSE AGREEMENTResearch License Agreement • May 8th, 2023 • Liquidia Corp • Pharmaceutical preparations • Delaware
This Research License Agreement (the “Agreement”) is entered into as of March 31, 2023 (the “Effective Date”) by and between Liquidia Technologies, Inc., a Delaware corporation, having its principal place of business at 419 Davis Dr., Suite 100, Morrisville, NC 27560 (“Liquidia”), and Glaxo Group Limited, a company organized and existing under the laws of England and having an office and place of business at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 ONN, United Kingdom (“GSK”). Liquidia and GSK are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
License for the Program Analyzer Generator (PAG)Research License Agreement • April 6th, 2023
This document is the research license agreement for the Program Analyzer Generator (PAG). The Program Analyzer Generator (PAG) is a tool for the generation of program analyzers.
RESEARCH LICENSE AGREEMENTResearch License Agreement • January 14th, 2021
RESEARCH LICENSE AGREEMENT (this “Agreement”), dated as of this ___ day of ＿＿＿＿＿, 2009 (the “Effective Date”), by and between Hiroshima University, a national university corporation duly organized under the laws of Japan, having a principal address at 1-3-2 Kagamiyama, Higashi-Hiroshima City, Hiroshima Pref., 739-8511, Japan (“University”), and [XYZ Corporation], a corporation duly organized under the laws of ______, having a principal place of business at ___________________, (“XYZ”).
RESEARCH LICENSE AGREEMENTResearch License Agreement • September 17th, 2020 • Colorado
This Agreement is entered into on ______________, 202X, between COLORADO SCHOOL OF MINES, located at 1500 Illinois Street, Golden, CO 80401 ("CSM") and [FULL COMPANY NAME], a(n) [name of state] corporation located at [full address] ("LICENSEE").
Subject: 1st Amendment to research license agreement to adapt into test booklet report format and use the WISC-IV Integrated Digit Span and Spatial Span subtests, the WAIS-IV Digit Span subtest, and the WMS-III Spatial Span subtest, plus applicable...Research License Agreement • December 3rd, 2018
This is the First Amendment (1st Amendment) to our Research License Agreement which became effective when fully signed on December 14, 2012 (the "Agreement"), to adapt the above subtests into test booklet format, with other assessments, for use in your research study titled “Chronic Kidney Disease in Children (CKiD) Longitudinal Study”. This 1st Amendment is effective upon receipt.
ATTENTION: With acquisition of the ATCOR4 software you agree to the following license contract.Research License Agreement • March 1st, 2003
Whereas the ‘Licensor’ is the company ‘ReSe Applications Schläpfer’ of Wil (Switzerland) and the Licensee is the company, institute, or individual acquiring the software. The terms ‘Software’ and ‘ATCOR4’ are used for the com- plete software installation as distributed through the web.
Research License Agreement Between Erasmus University and Self-Management Resource CenterResearch License Agreement • January 31st, 2024
This Agreement between SELF-MANAGEMET RESOURCE CENTER ("SMRC"), a company having powers under the laws of the State of California, and Erasmus University Medical Center Rotterdam (“Research Licensee"), an entity having a principal place of business at Wytemaweg 80,
NORTH CAROLINA STATE UNIVERSITY RESEARCH LICENSE AGREEMENTResearch License Agreement • February 12th, 2019
This Agreement is made by and between North Carolina State University (hereinafter referred to as “NCSU”), a constituent institution of the University of North Carolina and an educational institution organized under the laws of North Carolina, and having its principal office at Campus Box 8210, Raleigh, North Carolina 27695-8210, and ________ (“hereinafter referred to as “Licensee”), a corporation having its principal place of business at ________________________.
EX-10.9 21 b63782inexv10w9.htm EX-10.9 RESEARCH LICENSE AGREEMENTResearch License Agreement • May 5th, 2020
Exhibit 10.9 Confidential Treatment has been requested for portions of this document marked with asterisks. RESEARCH AND LICENSE AGREEMENT This Agreement, effective as of April 1, 2006 (the “Effective Date”), is by and between: NEW YORK UNIVERSITY (hereinafter “NYU”), a corporation organized and existing under the laws of the State of New York and having a place of business at 70 Washington Square South, New York, New York 10012 AND INTELLECT NEUROSCIENCES, INC. (hereinafter “INI”), a corporation organized and existing under the laws of the State of Delaware having its principal office at 7 West 18th Street, 9th Floor, New York, New York 10011. RECITALS WHEREAS, Drs. Blas Frangione, Thomas Wisniewski, and Einar Sigurdsson of NYU (hereinafter “the NYU Scientists”) have made certain inventions relating to use of a vaccine for the mitigation, prophylaxis or treatment of Alzheimer’s Disease, all as more particularly described in the U.S. and foreign patent applications and patents owned by
NATIONAL INSTITUTE OF STANDARDS AND TECHNOLOGY RESEARCH LICENSE AGREEMENTResearch License Agreement • May 23rd, 2016 • District of Columbia
This Agreement is entered into by and between the National Institute of Standards and Technology (NIST), a primary operating unit of the United States Department of Commerce, having offices at 100 Bureau Drive, Gaithersburg, MD 20899-2200, and [Insert Name] (LICENSEE) having a place of business at [Insert Address].
RESEARCH & LICENSE AGREEMENT by and between ACHILLION PHARMACEUTICALS, INC. and FOB SYNTHESIS, INC.Research & License Agreement • May 7th, 2008 • Achillion Pharmaceuticals Inc • Pharmaceutical preparations • New York
This agreement (the “Agreement”), dated the 4th day of April, 2008 (the “Effective Date”), is by and between Achillion Pharmaceuticals, Inc., a Delaware corporation (“Achillion”), and FOB Synthesis, Inc., a Georgia corporation (“FOB”).
CleanAmpTM dUTP CleanAmp™ Products: Patent Pending | RESEARCH LICENSE AGREEMENTResearch License Agreement • November 22nd, 2024
TERMS AND CONDITIONS CleanAmp™ products and/or technology incorporated therein (hereinafter “Products”) and their use may be covered by one or more patents or pending Patent Applications If you do not agree to use the Products you have purchased pursuant to the terms and conditions set out in this Research License Agree- ment, please contact TriLink BioTechnologies, Inc within ten days of receipt to return the unused and unopened Products for a full refund; provided, however, that custom-made Products may not be returned for a refund
